Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.1.409NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.83NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.310NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.362.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.162NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Y.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.86NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.154NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.4.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.2.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.41NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.137NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.446NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.76 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.398NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.163NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
P.3 (Theta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.38.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XAVNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BE.1.4.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBC.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BM.4.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.20NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.77NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.1.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LB.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.3.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XDYNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.18.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.4.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KS.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
MM.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.48.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.4.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
MC.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LB.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LP.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.50.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
MH.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LB.1.3.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LB.1.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.3.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LB.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.2.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
MA.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KP.3.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LB.1.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.81NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CH.1.1.20NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used